Efficacy of orally administered T-705 pyrazine analog on lethal West Nile virus infection in rodents

Antiviral Research

Volumn 80, Issue 3, 2008, Pages 377-379

  Morrey, John D ^a   Taro, Brandon S ^a   Siddharthan, Venkatraman ^a   Wang, Hong ^a   Smee, Donald F ^a   Christensen, Andrew J ^a   Furuta, Yousuke ^b  

^a UTAH STATE UNIVERSITY   (United States)

^b TOYAMA CHEMICAL CO LTD   (Japan)

Author keywords

6 Fluoro 3 hydroxy 2 pyrazinecarboxamide; Hamsters; Mice; T 705; West Nile virus

Indexed keywords

6 FLUORO 3 HYDROXY 2 PYRAZINECARBOXAMIDE; AMPLIGEN; PYRAZINE DERIVATIVE; T 705; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HAMSTER; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RODENT; SURVIVAL RATE; VIRUS INFECTION; WEST NILE FLAVIVIRUS;

ADMINISTRATION, ORAL; AMIDES; ANIMALS; BRAIN; CRICETINAE; DISEASE MODELS, ANIMAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MESOCRICETUS; MICE; MICE, INBRED C57BL; PYRAZINES; WEST NILE FEVER; WEST NILE VIRUS;

CRICETINAE; MUS; RODENTIA; WEST NILE VIRUS;

EID: 56349130559     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2008.07.009     Document Type: Article

References (10)

1. Anonymous, 2007. Toyama starts U.S. trials of polymerase inhibitor. FDAnews Drug Pipeline Alert, vol. 4.
2. Furuta Y., Takahashi K., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., Watanabe Y., Narita H., and Shiraki K. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob. Agents Chemother. 46 (2002) 977-981
3. Furuta Y., Takahashi K., Kuno-Maekawa M., Sangawa H., Uehara S., Kozaki K., Nomura N., Egawa H., and Shiraki K. Mechanism of action of T-705 against influenza virus. Antimicrob. Agents Chemother. 49 (2005) 981-986
4. Gowen B.B., Wong M.H., Jung K.H., Sanders A.B., Mendenhall M., Bailey K.W., Furuta Y., and Sidwell R.W. In vitro and in vivo activities of T-705 against arenavirus and bunyavirus infections. Antimicrob. Agents Chemother. 51 (2007) 3168-3176
5. Morrey J.D., Day C.W., Julander J.G., Blatt L.M., Smee D.F., and Sidwell R.W. Effect of interferon-alpha and interferon-inducers on West Nile virus in mouse and hamster models. Antivir. Chem. Chemother. 15 (2004) 101-109
6. Morrey J.D., Siddharthan V., Olsen A.L., Roper G.Y., Wang H.C., Baldwin T.J., Koenig S., Johnson S., Nordstrom J.L., and Diamond M.S. Humanized monoclonal antibody against West Nile virus E protein administered after neuronal infection protects against lethal encephalitis in hamsters. J. Infect. Dis. 194 (2006) 1300-1308
7. Morrey J.D., Siddharthan V., Olsen A.L., Wang H., Julander J.G., Hall J.O., Li H., Nordstrom J.L., Koenig S., Johnson S., and Diamond M.S. Defining the limit of effective treatment for West Nile virus neurological infection with a humanized neutralizing monoclonal antibody. Antimicrob. Agents Chemother. 51 (2007) 2396-2402
8. Morrey J.D., Smee D.F., Sidwell R.W., and Tseng C.K. Identification of active compounds against a New York isolate of West Nile virus. Antivir. Res. 55 (2002) 107-116
9. Sidwell R.W., Barnard D.L., Day C.W., Smee D.F., Bailey K.W., Wang M.-H., Morrey J.D., and Furuta Y. Efficacy of orally administered T-705 on lethal avian influenza A (H5N1) virus infections in mice. Antimicrob. Agents Chemother. 51 (2007) 845-851
10. Takahashi K., Furuta Y., Fukuda Y., Kuno M., Kamiyama T., Kozaki K., Nomura N., Egawa H., Minami S., and Shiraki K. In vitro and in vivo activities of T-705 and oseltamivir against influenza virus. Antivir. Chem Chemother 14 (2003) 235-241